Neurobiomarkers – Disease indicators

Using health informatics, longitudinal and cross-sectional studies in order to identify early biomarkers of ageing-related neurological disorders.

theme-2-large

Background

In order to prevent, minimise or reverse the loss of brain function associated with ageing-related neurological disorders, it's essential to be able to accurately and objectively measure biomarkers that can predict disease status and treatment efficacy.

Although some biomarkers show promise, less invasive, easily accessible and novel markers and disease indicators are needed.

Disease susceptibility and initiating mechanisms vary between individuals due to lifestyle and genetics. So early disease-associated biomarkers may also vary. Thus understanding patient groups within each disease group is important. The BRNZ's ability to undertake this intensive patient research is one of our major advantages.

Internationally, BRNZ have established a unique cross-sectional and longitudinal cohorts in both healthy and aging populations, and those with stroke and neurodegenerative disorders. We will complement this with new cohorts via the Dementia Prevention Research Clinics established in Theme 4.

Leadership Group

  • Prof Tim Anderson
  • Prof Ian Kirk
  • Prof Richie Poulton
  • Prof Russell Snell
  • Dr Joanna Williams

Clinical Leaders and Researchers: Prof Wickliffe Abraham, Assoc Prof Donna Addis, Prof Tim Anderson, Prof Alan Barber, Dr Lubica Beňušková, Assoc Prof Michael Black, Prof Garth Cooper, Dr Nick Cutfield, Prof John Dalrymple-Alford, Prof Tim David, Prof Mike Dragunow, Prof Richard Faull, Prof Valery Feigin, Prof Ngaire Kerse, Prof Ian Kirk, Dr Ping Liu, Dr Tracy Melzer, Prof Louise Nicholson, Prof Richie Poulton, Assoc Prof Cristin Print, Prof Dirk De Ridder, Dr Richard Roxburgh, Prof Russell Snell, Assoc Prof Barry Snow, Prof Warren Tate, Assoc Prof Lynnette Tippett, Dr Joanna Williams.